A KRAS (Kirsten rat sarcoma viral oncogene)-activating mutation is a potent mechanism of resistance to EGFR inhibitors and occurs in around 40% of patients with advanced CRC, having a negative impact on overall survival (OS) [12]. The gene discussed is KRAS; the disease is colorectal carcinoma.